Investor Update

Basel, 22 November 2013

Anti-Cancer Agent “Avastin” obtained Approval for Additional Indication of Ovarian Cancer in Japan

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.